Alla Khalfin, DO
Endocrinology, Diabetes & Metabolism · Syosset, NYNPI 1528259843
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2019 at $11,842 and has fallen 70.4% since, to $3,499 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,078 payments — averaging $44.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Sanofi-aventis U.S. LLC$9K
- Amneal Pharmaceuticals LLC$6K
- Corcept Therapeutics$4K
- Novo Nordisk$2K
- Amgen$2K
- plus $14K from 51 others
Across 2 payments — averaging $3526.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ionis Pharmaceuticals, Inc.$7K
What the payments were for
- Consulting fees$8,22117%
- Speaking & faculty fees$13,69528%
- Travel & lodging$8552%
- Food & beverage$22,51147%
- Education$2,9526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,233 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 247 | $484,267 |
| MounjaroTirzepatide | 302 | $433,187 |
| JardianceEmpagliflozin | 164 | $220,726 |
| TrulicityDulaglutide | 112 | $205,705 |
| FarxigaDapagliflozin Propanediol | 84 | $122,561 |
| Tresiba Flextouch U-200Insulin Degludec | 82 | $120,536 |
| JanuviaSitagliptin Phosphate | 66 | $80,611 |
| RybelsusSemaglutide | 27 | $62,341 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 40 | $55,377 |
| TradjentaLinagliptin | 48 | $50,489 |
| GenotropinSomatropin | 17 | $34,968 |
| JanumetSitagliptin Phos/Metformin Hcl | 29 | $33,721 |
| AfrezzaInsulin Regular, Human | 15 | $32,340 |
| Novolog FlexpenInsulin Aspart | 56 | $30,696 |
| ProliaDenosumab | 16 | $27,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,709 | $643,518425 claims |
| Novo NordiskOzempic, Rybelsus | $2,169 | $546,607274 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $1,973 | $286,532223 claims |
| MerckJanuvia, Janumet, Janumet Xr | $421 | $141,811115 claims |
| AstraZenecaFarxiga | $10,962 | $122,56184 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $8,870 | $55,37740 claims |
| Mannkind CorporationAfrezza | $826 | $32,34015 claims |
| AmgenProlia | $2,028 | $27,95816 claims |
| AbbVieSynthroid, Armour Thyroid | $946 | $19,600227 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $6,244 | $5,867332 claims |
| IBSA Pharma Inc.Tirosint | $314 | $2,52611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Syosset
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.